Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tela Bio to $12 from $15 and keeps an Overweight rating on the shares following the Q4 report. Management initiated 2024 sales guidance of just below 30%, which is conservative given the sales force is righted at this point, the analyst tells investors in a research note. The firm has confidence that 2025 and 2026 “can be further inflections on the topline.” It continues to believe Tela has a highly differentiated mesh technology that will capture meaningful share in the coming years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELA:
- TELA Bio Announces Investor Update and Hernia Mesh Launch
- TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
- TELA Bio announces U.S. commercial launch of LIQUIFIX
- TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
- TELA Bio anounces sale of distribution rights for wound care product